MedTrace Logo

Renin Angiotensin System Study (RASS/B-RASS)

NCT00143949 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 285

Last updated 2008-11-06

No results posted yet for this study

Summary

To determine if renin angiotensin medications can prevent or delay the onset of diabetic kidney disease.

Conditions

Interventions

DRUG

enalapril

DRUG

losartan

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Merck Frosst Canada Ltd.

    collaborator INDUSTRY

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Michael Mauer, MD

    lead INDIV

Principal Investigators

  • S M Mauer, MD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
61 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1997-03-31
Primary Completion
2007-03-31
Completion
2008-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00143949 on ClinicalTrials.gov